Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from A375 melanoma parental and persister cells

ABSTRACT: Expression data from A375 melanoma parental and persister cells

PROVIDER: PRJNA566397 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from A375 melanoma parental and persister cells

Project description:Identify transcriptionnally and translationally regulated mRNA in melanoma parental and persister cells In this dataset, we include expression data of A375 melanoma drug-naïve parental cells and A375 melanoma persister cells that survived from BRAF and MEK inhibition. The expression data are studied in both total RNA and polysome-bounded RNA.

2019-09-20 | GSE137724 | GEO

A375 melanoma parental and persister cells

Project description:A375 melanoma parental and persister cells

| PRJNA566394 | ENA

m6A-seq of melanoma parental and persister cells

Project description:We study the m6A distribution on mRNAs from melanoma drug-naïve parental and persister cells treated with BRAF and MEK inhibitors.

2019-09-20 | GSE137725 | GEO

m6A-seq of melanoma parental and persister cells

Project description:m6A-seq of melanoma parental and persister cells

| PRJNA566396 | ENA

Expression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib

Project description:Vemurafenib is a BRAF inhibitor with specificity for the most common BRAF mutant encountered in melanomas (BRAFV600E). Vemurafenib suppresses the proliferation of BRAF mutant human melanoma cells by suppressing downstream activation of the MEK/ERK mitogen activated protein kinases. We used microarrays to examine the transcriptional response of a vemurafenib-sensitive BRAFV600E human melanoma cell line (A375) to vemurafenib in order to further delineate the mechanisms by which BRAFV600E drives cell proliferation and energy metabolism in human melanoma. BRAFV600E A375 human melanoma cells were treated with vehicle (0.1% DMSO) or 10 uM vemurafenib for 24 h after which total RNA was extracted. Cells were prepared and RNA was extracted in 3 separate batches (three different cell stocks on three separate days) providing three independent replicates (n=3). Paired replicates (prepared from the same stock of cells on the same day) are denoted by A, B and C.

2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress

A375 melanoma parental and persister cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-09-20 | GSE137726 | GEO

Expression data from catalase stably transfected A375 human melanoma cells

Project description:Reactive oxygen species (ROS) are implicated in tumor transformation by modulating proteins involved in differentiation, proliferation and invasion. In order to identify genes that may support melanoma progression or regression after an antioxidant system (AOS) response, we developed and characterized a human melanoma cell model with different levels of ROS by stably overexpressing the antioxidant enzyme catalase in A375 amelanotic melanoma cells, and whole genome gene expression patterns were analyzed by microarrays. We used gene expression microarrays to study the AOS global response to catalase overexpression and to identify up-regulated and down-regulated genes during progression or regression of melanoma.

2018-10-29 | GSE74611 | GEO

Gene expression profiling of isogenic malignant melanoma A375-BRAFV600E/NRASQ61 and A375-BRAFV600E/NRASQ61K cell lines

Project description:BRAF-inhibitor (BRAFi)-resistance compromises long term survivorship of malignant melanoma patients, and mutant NRAS is a major mediator of BRAFi-resistance. We have employed NanoString nCounterTM transcriptomic analysis of isogenic human malignant melanoma cells that differ only by NRAS mutational status (BRAFi-sensitive A375-BRAFV600E/NRASQ61 versus BRAFi-resistant A375-BRAFV600E/NRASQ61K), identifying modulation of specific gene expression networks as a function of NRASQ61K-status.

2021-09-23 | GSE184633 | GEO

A375 melanoma cells treated with leflunomide 25uM

Project description:Human A375 melanoma cells were treated with leflunomide 25uM for 3 days, then RNA harvested 6 arrays

2011-03-30 | E-GEOD-24526 | biostudies-arrayexpress

Expression analysis of A375 melanoma cells with silenced BMI-1 or not

Project description:Our studies demonstrate that BMI-1 plays a crucial role in the EMT process and drug resistance in melanoma. Silencing Bmi-1 significantly inhibites the aggressive behavior and improves the chemosensitivity to all-trans retinoic acid on melanoma cells. We compared the different genes expression of A375-vector and A375-BMI-1 cells for exploring the underlying mechanisms of BMI-1 regulation on melanoma.

2021-06-01 | GSE115644 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data